Fig. 5
From: A microengineered vascularized bleeding model that integrates the principal components of hemostasis
Inhibition of factor VIII and blood from hemophilia A patients reduce fibrinogen/fibrin accumulation at the injury site and impair hemostasis. a When healthy blood was treated with an antibody against A2 domain of Factor VIII (mAb 2–76), there was no difference in the total surface area of adhered platelets at the injury site compared to that of vehicle control conditions. b However, inhibition of factor VIII resulted in a significant reduction of fibrinogen/fibrin accumulation at later time points (10 and 15 min after the mechanical injury). The error bars in the graphs show standard errors (control n = 4, mAb 2–76 n = 4). Double asterisk (**) shows P-value < 0.05 by Student's t-test. c Antibody-treated blood sample exhibited “re-bleeding” and failed to achieve hemostasis during the entire experimental time frame (d). e Severe hemophilia A patient blood samples also failed to achieve hemostasis and continued bleeding over the entire experimental time course. f Fibrinogen/fibrin accumulation (green) was also markedly decreased in severe hemophilia A patient blood samples at the wound site as compared to that of healthy control blood, although platelet (red) adhesion and accumulation were similar between the two conditions. Scale bar = 50 µm. Bars in graphs represent median values
